Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Ivonescimab for the Treatment of Thymic Cancer

Phase 2

Not yet recruiting

Conditions: Thymus Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Ivonescimab
Procedure: Magnetic Resonance Imaging
Other: Questionnaire Administration

First Posted Date: 2025-05-20

Last Posted Date: 2025-05-20

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT06980077

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Impact of Artificial Intelligence on Breast Cancer Screening

Not Applicable

Not yet recruiting

Conditions: Breast Cancer Screening
Artificial Intelligence (AI)

First Posted Date: 2025-04-18

Last Posted Date: 2025-05-16

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 154474

Registration Number: NCT06934239

Locations: 🇺🇸
University of California Los Angeles Health System, Los Angeles, California, United States
🇺🇸
University of Washington Health System, Seattle, Washington, United States

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 1

Not yet recruiting

Conditions: T-cell-prolymphocytic Leukemia
Cutaneous T-Cell Lymphoma Refractory

Interventions: Drug: Duvelisib
Drug: Venetoclax

First Posted Date: 2025-02-06

Last Posted Date: 2025-04-15

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT06810778

Locations: 🇺🇸
David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California, United States

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Phase 2

Recruiting

Conditions: DLL3-expressing Tumors
Advanced Tumors

Interventions: Drug: Tarlatamab treatment

First Posted Date: 2025-01-23

Last Posted Date: 2025-04-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 29

Registration Number: NCT06788938

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸
UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States

and more 1 locations

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Phase 1

Recruiting

Conditions: Glioma
Malignant Brain Neoplasm
Meningioma
Metastatic Malignant Neoplasm in the Brain

First Posted Date: 2024-10-21

Last Posted Date: 2025-01-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT06650163

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

Not Applicable

Recruiting

Conditions: Head and Neck Carcinoma
Localized Head and Neck Carcinoma
Metastatic Head and Neck Carcinoma
Recurrent Head and Neck Carcinoma

Interventions: Procedure: Personalized ultrafractionated stereotactic adaptive radiotherapy
Radiation: Volume Modulated Arc Therapy
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Other: Best Practice
Behavioral: University of Washington Quality of Life Scale, Version 4
Behavioral: Functional Assessment of Cancer Therapy-Head & Neck

First Posted Date: 2024-08-27

Last Posted Date: 2025-01-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 43

Registration Number: NCT06572423

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States

A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers

Not Applicable

Not yet recruiting

Conditions: Colorectal Carcinoma

Interventions: Other: Best Practice
Other: Communication Intervention
Other: Electronic Health Record Review
Other: Coordination
Other: Educational Intervention
Other: Interview
Other: Referral
Other: Informational Intervention
Behavioral: Patient Navigation
Other: Text Message-Based Navigation Intervention

First Posted Date: 2024-08-23

Last Posted Date: 2025-01-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1500

Registration Number: NCT06568016

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Phase 1

Not yet recruiting

Conditions: Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Cervical Squamous Cell Carcinoma
Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8

Interventions: Biological: Bevacizumab
Procedure: Biospecimen Collection
Radiation: Brachytherapy
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Drug: Paclitaxel
Biological: Pembrolizumab
Other: Questionnaire Administration

First Posted Date: 2024-08-09

Last Posted Date: 2025-05-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 35

Registration Number: NCT06543576

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California San Diego (UCSD), San Diego, California, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

and more 1 locations

Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers

Not Applicable

Recruiting

Conditions: Cervical Cancer
Endometrial Cancer

Interventions: Radiation: External beam Radiotherapy

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 60

Registration Number: NCT06538337

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

Phase 3

Not yet recruiting

Conditions: Glioblastoma

Interventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging
Procedure: Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
Procedure: Magnetic Resonance Imaging
Radiation: Radiation Therapy
Procedure: Surgical Procedure
Drug: Temozolomide

First Posted Date: 2024-06-07

Last Posted Date: 2025-05-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 60

Registration Number: NCT06448286

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Home Terms & Conditions Privacy Policy